论文部分内容阅读
目的探讨依达拉奉对高血压脑出血患者血清S-100β蛋白、神经元烯醇化酶(neuron-specific enolase,NSE)的影响。方法 2012年7月—2014年12月收治的高血压脑出血患者82例,随机分为常规治疗组42例和依达拉奉组40例。常规治疗组给予常规治疗,依达拉奉组在常规治疗基础上加用依达拉奉,手术均采用锁孔微创手术血肿清除。观察两组治疗前和治疗第3、5、7、14天血清中S-100β蛋白、NSE水平。计量资料组内比较采用配对t检验,组间比较采用t检验,P<0.05为差异有统计学意义。结果常规治疗组治疗后第3、5、7、14天血清S-100β蛋白水平分别为(0.317±0.094)、(0.295±0.087)、(0.198±0.024)、(0.148±0.038)μg/L,依达拉奉组分别为(0.216±0.079)、(0.204±0.079)、(0.136±0.026)、(0.118±0.044)μg/L,两组比较差异均有统计学意义(t=5.254、4.951、11.228、3.309,均P<0.05)。常规治疗组治疗后第3、5、7、14天血清NSE分别为(21.60±4.32)、(18.48±3.86)、(14.67±3.71)、(11.62±3.75)U/ml,依达拉奉组分别为(19.78±3.59)、(14.64±3.25)、(11.46±3.42)、(9.48±3.39)U/ml,两组比较差异均有统计学意义(t=2.069、4.861、4.068、2.706,均P<0.05)。结论依达拉奉对高血压脑出血患者的神经元有保护作用,能有效改善神经功能缺损。
Objective To investigate the effect of edaravone on serum S-100β protein and neuron-specific enolase (NSE) in patients with hypertensive intracerebral hemorrhage. Methods From July 2012 to December 2014, 82 patients with hypertensive intracerebral hemorrhage were randomly divided into conventional treatment group (n = 42) and edaravone group (n = 40). The patients in the conventional treatment group were given routine treatment. Edaravone group was treated with edaravone on the basis of conventional treatment. All patients underwent minimally invasive keyhole operation with hematoma clearance. The serum levels of S-100β protein and NSE in the two groups before treatment and on the 3rd, 5th, 7th and 14th days of treatment were observed. Measurement data within the group using the paired t test, compared between groups using t test, P <0.05 for the difference was statistically significant. Results The serum levels of S-100β in the conventional treatment group were (0.317 ± 0.094), (0.295 ± 0.087), (0.198 ± 0.024) and (0.148 ± 0.038) μg / L on the 3rd, 5th, (0.216 ± 0.079), (0.204 ± 0.079), (0.136 ± 0.026) and (0.118 ± 0.044) μg / L respectively in the edaravone group, with significant difference between the two groups (t = 5.254,4.951, 11.228, 3.309, all P <0.05). The NSE of the 3rd, 5th, 7th and 14th day after treatment in the conventional treatment group were (21.60 ± 4.32), (18.48 ± 3.86), (14.67 ± 3.71) and (11.62 ± 3.75) U / ml, (19.78 ± 3.59), (14.64 ± 3.25), (11.46 ± 3.42) and (9.48 ± 3.39) U / ml respectively, there were significant differences between the two groups (t = 2.069,4.861,4.068,2.706, both P <0.05). Conclusion Edaravone can protect neurons in patients with hypertensive intracerebral hemorrhage and can effectively improve neurological deficits.